Aditxt, Inc. Increase (Decrease) in Accounts Receivable
Aditxt, Inc. (ADTX) reported Increase (Decrease) in Accounts Receivable of $11.97 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-20.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-05-20
- Aditxt, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $11.97K.
- Aditxt, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$39.18K.
- Aditxt, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$561.00.
- Aditxt, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-06-30 was -$2.38K.
- Aditxt, Inc. increase (decrease) in accounts receivable for fiscal 2025 was -$43.44K.
- Aditxt, Inc. increase (decrease) in accounts receivable for fiscal 2024 was -$364.89K.
- Aditxt, Inc. increase (decrease) in accounts receivable for fiscal 2023 was -$119.64K, a 127.31% decline from fiscal 2022.
- Aditxt, Inc. increase (decrease) in accounts receivable for fiscal 2022 was $438.12K, a 40.22% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month | Increase (Decrease) in Accounts Receivable 12 month as first filed |
|---|---|---|---|---|---|
| 2026-03-31 | $11.97K 10-Q · filed 2026-05-20 | -$27.21K derived: sum of 2 quarters · filed 2026-05-20 | -$27.77K derived: sum of 3 quarters · filed 2026-05-20 | -$30.14K derived: sum of 4 quarters · filed 2026-05-20 | |
| 2025-12-31 | -$39.18K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$39.74K derived: sum of 2 quarters · filed 2026-03-31 | -$42.12K derived: sum of 3 quarters · filed 2026-03-31 | -$43.44K 10-K · filed 2026-03-31 | |
| 2025-09-30 | -$561.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-18 | -$2.94K derived: sum of 2 quarters · filed 2025-11-18 | -$4.25K 10-Q · filed 2025-11-18 | -$312.52K derived: sum of 4 quarters · filed 2026-05-20 | |
| 2025-06-30 | -$2.38K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$3.69K 10-Q · filed 2025-08-14 | -$311.96K derived: sum of 3 quarters · filed 2026-05-20 | -$366.85K derived: sum of 4 quarters · filed 2026-05-20 | |
| 2025-03-31 | -$1.32K 10-Q · filed 2026-05-20 | -$309.59K derived: sum of 2 quarters · filed 2026-05-20 | -$364.48K derived: sum of 3 quarters · filed 2026-05-20 | -$384.93K derived: sum of 4 quarters · filed 2026-05-20 | |
| 2024-12-31 | -$308.27K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$363.16K derived: sum of 2 quarters · filed 2026-03-31 | -$383.61K derived: sum of 3 quarters · filed 2026-03-31 | -$364.89K 10-K · filed 2026-03-31 | |
| 2024-09-30 | -$54.89K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-18 | -$75.34K derived: sum of 2 quarters · filed 2025-11-18 | -$56.62K 10-Q · filed 2025-11-18 | -$11.00K derived: sum of 4 quarters · filed 2025-11-18 | |
| 2024-06-30 | -$20.45K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$1.73K 10-Q · filed 2025-08-14 | $43.89K derived: sum of 3 quarters · filed 2025-08-14 | $27.43K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $18.72K 10-Q · filed 2025-05-15 | $64.34K derived: sum of 2 quarters · filed 2025-05-15 | $47.88K derived: sum of 3 quarters · filed 2025-05-15 | $98.02K derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $45.62K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $29.16K derived: sum of 2 quarters · filed 2025-03-31 | $79.31K derived: sum of 3 quarters · filed 2025-03-31 | -$119.64K 10-K · filed 2025-03-31 | |
| 2023-09-30 | -$16.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-18 | $33.69K derived: sum of 2 quarters · filed 2024-11-18 | -$165.25K 10-Q · filed 2024-11-18 | $43.55K derived: sum of 4 quarters · filed 2024-11-18 | |
| 2023-06-30 | $50.15K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-19 | -$148.79K 10-Q · filed 2024-08-19 | $60.01K derived: sum of 3 quarters · filed 2024-08-19 | -$31.43K derived: sum of 4 quarters · filed 2024-08-19 | |
| 2023-03-31 | -$198.94K 10-Q · filed 2024-05-20 | $9.86K derived: sum of 2 quarters · filed 2024-05-20 | -$81.57K derived: sum of 3 quarters · filed 2024-05-20 | $80.24K derived: sum of 4 quarters · filed 2024-05-20 | |
| 2022-12-31 | $208.80K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $117.37K derived: sum of 2 quarters · filed 2024-04-16 | $279.18K derived: sum of 3 quarters · filed 2024-04-16 | $438.12K 10-K · filed 2024-04-16 | $36.77K 10-K · filed 2023-04-17 |
| 2022-09-30 | -$91.43K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $70.38K derived: sum of 2 quarters · filed 2023-11-14 | $229.31K 10-Q · filed 2023-11-14 | $273.35K derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $161.82K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $320.75K 10-Q · filed 2023-08-14 | $364.78K derived: sum of 3 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $158.93K 10-Q · filed 2023-05-15 | $202.96K derived: sum of 2 quarters · filed 2023-05-15 | |||
| 2021-12-31 | $44.03K derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-17 | $312.46K 10-K · filed 2023-04-17 | $89.84K 10-K · filed 2022-03-31 | ||
| 2021-09-30 | $268.43K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |